PYC
PYC THERAPEUTICS ORDINARYPYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC
PYC
PYC THERAPEUTICS ORDINARY
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 0.34% | — |
| 10 July | 0.34% | — |
| 9 July | 0.34% | — |
| 8 July | 0.34% | — |
| 7 July | 0.34% | — |
| 6 July | 0.34% | — |
| 3 July | 0.35% | — |
| 2 July | 0.36% | — |
| 1 July | 0.36% | — |
Pyc Therapeutics (PYC) Short Interest Summary
Pyc Therapeutics (PYC) currently has 0.34% of its shares sold short (3.3 million shares, worth approximately $5.6 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes PYC the #355 most shorted stock on the ASX most shorted list. Short interest in PYC is down 0.00% over the past week and down 0.06% over the past month. PYC is part of the Health Care sector on the ASX.
Recent PYC Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 0.34% | 3.3M | $1.55 |
| 10 July 2026 | 0.34% | 3.3M | $1.55 |
| 9 July 2026 | 0.34% | 3.3M | $1.52 |
| 8 July 2026 | 0.34% | 3.4M | $1.56 |
| 7 July 2026 | 0.34% | 3.3M | $1.53 |
| 6 July 2026 | 0.34% | 3.3M | $1.55 |
| 3 July 2026 | 0.35% | 3.4M | $1.53 |
| 2 July 2026 | 0.36% | 3.5M | $1.62 |
| 1 July 2026 | 0.36% | 3.5M | $1.68 |
| 30 June 2026 | 0.36% | 3.5M | $1.68 |
PYC Short Selling — Frequently Asked Questions
What is Pyc Therapeutics (PYC)'s current short interest?
Pyc Therapeutics (PYC) currently has a short interest of 0.34% of total shares outstanding. This means 0.34% of PYC's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is PYC heavily shorted on the ASX?
PYC has a relatively low short interest of 0.34%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for PYC investors?
Short interest in PYC shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.34%, PYC's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this PYC short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for PYC.